$200M for the Doctor’s New Brain: OpenEvidence Is the ChatGPT of Healthcare

OpenEvidence, the AI health tech company aiming to become the “ChatGPT for doctors,” has raised a massive $200 million Series B at a $6 billion valuation . This new funding marks one of the largest health AI rounds to date and signals strong investor conviction in the startup’s approach to transforming medical decision-making through generative AI.

Founded by Stanford-affiliated researchers, OpenEvidence is building an AI-powered assistant that helps physicians make faster, more accurate clinical decisions. The system pulls from vast volumes of peer-reviewed medical literature and structured data to answer questions with citation-backed precision — a critical differentiator from consumer-grade AI tools. With a focus on clinical-grade reliability , OpenEvidence is already being piloted at major U.S. health systems.

The funding will be used to scale OpenEvidence's deployments across hospitals and clinics, invest in regulatory pathways, and enhance the platform’s capabilities in areas such as rare diseases, diagnostics, and treatment planning. The company is also planning to expand its engineering and go-to-market teams aggressively over the next year.

As the AI race heats up in healthcare, OpenEvidence's approach—rooted in scientific rigor and medical relevance—is positioning it as a category-defining player in clinical AI. The company’s founders have said the ultimate goal is to create an AI co-pilot for every doctor , augmenting their ability to deliver evidence-based, high-quality care at scale.

Source: TechCrunch
                 The New York Times
                 Axios

M.A.